Table 3.
RFP+CoRL that migrated to the IGC
| Data from IGC | Total No. of Glomeruli in Kidney Cortex | Total Glomeruli in Kidney Cortex That Contain RFP+CoRL, % | Total No. RFP+CoRL Detected in All Glomeruli in Kidney Cortex | Average No. RFP+CoRL per Glomerulus within Glomeruli Containing Such Cells | Labeled RFP+CoRL That Have Migrated from JGC to IGC |
|---|---|---|---|---|---|
| Baseline (no FSGS) | |||||
| H2O alone | 226.68±25.17 | 0.13±0.00 | 0.67±1.15 | 2 | 0.17±0.29 |
| FSGS day 28 | |||||
| FSGS+H2O | 214.6±26.04 | 4.88±0.024 | 21.2±8.7 | 2.04 | 5.2±2.32 |
| (P=0.54 versus H2O) | (P=0.01 versus H2O) | (P=0.01 versus H2O) | (P<0.05 versus H2O) | (P<0.01 versus H2O) | |
| FSGS+hydralazine | 196±4 | 3.07±0.01 | 17.3±6.4 | 2.89 | 2.83±0.98 |
| (P=0.28 versus FSGS H2O) | (P=0.27 versus FSGS H2O) | (P=0.53 versus FSGS H2O) | (P=0.15 versus FSGS H2O) | (P=0.15 versus FSGS H2O) | |
| FSGS+enalapril | 188.6±32.89 | 25.69±0.06a | 162.6±108.4 | 3.37b | 10.7±11.03 |
| (P=0.36 versus FSGS hydralazine) | (P=0.001 versus FSGS hydralazine) | (P<0.03 versus FSGS hydralazine) | (P=0.67 versus FSGS hydralazine) | (P=0.20 versus FSGS hydralazine) | |
| FSGS+losartan | 210.8±30.74 | 12.26±0.02c | 88±32.2 | 3.38d | 7.23±3.66 |
| (P=0.45 versus FSGS hydralazine) | (P=0.001 versus FSGS hydralazine) | (P=0.01 versus FSGS hydralazine) | (P=0.4 versus FSGS hydralazine) | (P=0.09 versus FSGS hydralazine) |
a
In FSGS, percentage of glomeruli with RFP+CoRL is increased 8.37-fold by enalapril compared with hydralazine treatment.
b
In FSGS, the number of RFP+CoRL was 1.16-fold higher in the enalapril-treated group compared with hydralazine treatment.
c
In FSGS, the percentage of glomeruli containing RFP+CoRL was four-fold higher in losartan group compared with hydralazine treatment.
d
In FSGS, within individual glomeruli containing RFP+CoRL, the number of RFP+CoRL were increased 1.17-fold by losartan compared with hydralazine treatment.